Strong Global Entertainment Inc
Change company Symbol lookup
Select an option...
SGE Strong Global Entertainment Inc
CNSP CNS Pharmaceuticals Inc
SMTC Semtech Corp
EU enCore Energy Corp
CJET Chijet Motor Co Inc
LAKE Lakeland Industries Inc
JWEL Jowell Global Ltd
SMAR Smartsheet Inc
FOXA Fox Corp
SCVFF Scotch Creek Ventures Inc

Company profile

Strong Global Entertainment, Inc. manufactures and distributes large format projection screens, provides managed services, technical support and related products and services primarily to cinema exhibitors, theme parks, educational institutions, and similar venues. The Company also provides maintenance, repair, installation, network support services and other services to cinema operators, primarily in the United States. Its field service and Network Operations Center (NOC) staff work hand in hand to monitor and resolve system and other issues for its customers. The Company operates three businesses: Strong/MDI Screen Systems, Inc., the screen and projection coatings supplier in the world; Strong Technical Services, Inc., which provides comprehensive managed services with 24/7/365 support nationwide and distributes cinema equipment; and Strong Studios, Inc., which develops and produces original feature films and television series and acquires rights to distribute content globally.

Day's Change
-0.06 (-1.82%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 32,517 shares is on pace to be much greater than SGE's 10-day average volume of 25,520 shares.


NeuroMetrix to Exhibit Quell(R) Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

9:00 am ET March 21, 2023 (Globe Newswire) Print
NeuroMetrix to Exhibit Quell(R) Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual MeetingGlobeNewswireMarch 21, 2023

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in patients with fibromyalgia will be presented.

Fibromyalgia is a chronic condition characterized by generalized pain, fatigue, poor sleep, memory and concentration impairments, mood disorders and other disabling symptoms. The prevalence of fibromyalgia is estimated to be 2 to 6 percent of the U.S. adult population (5 to 15 million people). Quell Fibromyalgia utilizes proprietary wearable neuromodulation technology and is the only FDA authorized medical device to help reduce the symptoms of fibromyalgia. Conference attendees are encouraged to visit the Company's booth #32 for a demonstration and to review prescribing details.

The two scientific posters listed below will be presented live on Friday, March 24 and will be available for review throughout the conference.

  • Wearable Lower-Extremity Transcutaneous Electrical Nerve Stimulation (TENS) May Improve Self-Reported Balance Impairment in Subjects with Fibromyalgia: An Exploratory Post-Hoc Analysis

    Balance impairment and falls are common in individuals with fibromyalgia. Data from a recently completed double-blind, randomized, sham-controlled trial of Quell in 119 subjects with fibromyalgia was analyzed. Self-reported balance impairment was assessed on an 11-point numerical rating scale. The median balance at baseline was 5 (IQR 2-7). Balance impairment decreased following 3-months of active (-1.32±0.30, p<0.001) but not sham (-0.35±0.34, p=0.300) treatment. The group difference was significant (-0.97±0.46, p=0.039). Quell may improve self-reported balance impairment in patients with fibromyalgia.
  • Fibromyalgia Patients with Self-Reported Weather Insensitivity Exhibit an Enhanced Treatment Response to Wearable Lower-Extremity Transcutaneous Electrical Nerve Stimulation (TENS)

    Most individuals with fibromyalgia report that weather changes exacerbate their symptoms. However, little is known about the minority that is insensitive to the effects of weather. An analysis of real-world data from 766 individuals with fibromyalgia was conducted. Participants without weather sensitivity reported greater reductions in pain-intensity, pain-interference with sleep and pain-interference with activity compared to those with weather sensitivity. If the treatment benefits of weather insensitivity can be determined, it may be possible to optimize outcomes in the overall population of fibromyalgia patients.

"We are pleased to contribute to the unmet need for safe and effective treatments for people with fibromyalgia. AAPM is an opportunity for us to exchange clinical and scientific information with pain medicine physicians who are managing patients with fibromyalgia," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer, NeuroMetrix. "We are also looking forward to presenting new clinical data that builds on the use of Quell in fibromyalgia. Our preliminary finding that Quell improves self-reported balance is intriguing and supports our hypothesis that the Quell modulates both analgesic and non-analgesic neural circuits."

Quell Fibromyalgia Indications

Quell Fibromyalgia is a transcutaneous electrical nerve stimulation (TENS) device indicated as an aid for reducing the symptoms of fibromyalgia in adults with high pain sensitivity. The device may be used during sleep.


The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109. The product labeling should be reviewed for a complete list of contraindications, precautions and warnings.

For more information visit

About Quell Technology

Quell is an advanced, non-invasive, neuromodulation technology that is covered by 24 U.S. utility patents. It is the only wearable neuromodulator that is enabled by a proprietary microchip to provide precise, high-power nerve stimulation in a form factor the size of a credit card. Quell utilizes position and motion sensing to automatically adjust stimulation for an optimal user experience both day and night. The device supports Bluetooth(R) low energy (BLE) to communicate with mobile apps for multiple smartphone platforms.

About NeuroMetrix

NeuroMetrix is an innovation-driven company with a mission to improve individual and population health through novel medical devices and technology solutions for neurological disorders and pain syndromes. The Company has three commercial products. DPNCheck(R) is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE(R) is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell(R) Fibromyalgia is a wearable neuromodulator that is the only FDA-authorized medical device to help reduce the symptoms of fibromyalgia. For more information, visit

Source: NeuroMetrix, Inc.

Thomas T. Higgins

SVP and Chief Financial Officer


Primary Logo

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.